Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Status:
Recruiting
Trial end date:
2025-07-25
Target enrollment:
Participant gender:
Summary
This research is designed to determine if experimental treatment with PARP inhibitor,
AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has
anti-cancer activity in patients with advanced solid tumors.